Liposomes

• US 20040170560A1
• Filed: 11/07/2003
• Published: 09/02/2004
• Est. Priority Date: 05/10/2001
• Status: Abandoned Application

• Current Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Original Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Inventors: Fossheim, Sigrid, Odegardstuen, Liv Ingrid
• Application Number:
  US10/477,157
• Publication Number:
  US 20040170560A1
• Time in Patent Office: Days
• US Class Current: 424/1.29
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 51/1234 Liposomes
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Liposomes of a specific bilayer composition containing an entrapped modifying compound are claimed. The liposomes of the invention are suitable for the internalisation of a variety of materials, even following long-term storage. Suitable materials of the invention include radiometals, parmagnetic compounds, radioopaque compounds and prodrugs. Upon internalisation, the material reacts chemically with the entrapped modifying compound such that said material remains internalised within the liposomes of the invention. Also claimed in the present invention are the liposomes containing internalised material and kits for their preparation. Furthermore, the use of said liposomes containing internalised material for the imaging infection, inflammation or tumour in a human is claimed.

Claims

1. ) A liposome comprising:

i) a neutral phospholipid,

ii) a negatively charged phospholipid,

iii)a sterol,

having a modifying compound entrapped in the internal phase of said liposome;

wherein the modifying compound is a compound that is capable of irreversibly chemically modifying an internalisable material within said liposome following diffusion of said material across the phospholipid bilayer of said liposome, such that the irreversibly chemically modified material remains internalised within said liposome, and;

wherein the neutral phospholipid is present at 60-90 mole percent of the total lipid content, the negatively charged phospholipid is present at 2-20 mole percent of the total lipid content and the sterol is present at 5-25 mole percent of the total lipid content.

2. ) The liposome of claim 1 wherein the modifying compound is a reductant.

3. ) The liposome of claims 1 and 2 wherein the modifying compound is chosen from ascorbic acid, cysteine and glutathione.

4. ) The liposome of claim 3 wherein the modifying compound is glutathione.

5. ) The liposome of claims 1-4 wherein the proportion of the modifying compound present in the internal phase of said liposome is in the range 95-100% of the modifying compound present in the internal and external phases of said liposome.

6. ) The liposome of claims 1-5 wherein said internalisable material is chosen from a radioactive agent, a paramagnetic agent or a radioopaque agent.

7. ) The liposome of claims 1-6 wherein said internalisable material is a metal chelate.

8. ) The liposome of claim 7 wherein the metal of said metal chelate is chosen from a radiometal suitable for SPECT or PET imaging, a paramagnetic metal suitable for MRE or a radioopaque metal suitable for x-ray imaging.

9. ) The liposome of claims 7 and 8 wherein the metal of said metal chelate is selected from ^99mTc, ¹¹¹In, gadolinium, manganese or tungsten.

10. ) The liposome of claims 1-5 wherein said internalisable material is a prodrug.

11. ) The liposome of claims 1-10 wherein said sterol is present at 10-25 mole percent of the total lipid content.

12. ) The liposome of claims 1-11 wherein the fatty acyl chain length of said neutral phospholipid and that of said negatively charged phospholipid is in the range 14 to 20 carbon atoms.

13. ) The liposome of claims 1-12 wherein the fatty acyl chains of said neutral phospholipid and of said negatively charged phospholipid are of equal length.

14. ) The liposome of claims 1-13 wherein the fatty acyl chains of said neutral phospholipid and said negatively charged phospholipid are chosen from myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid and arachidonic acid.

15. ) The liposome of claims 1-14 wherein said neutral phospholipid is a phosphatidylcholine compound.

16. ) The liposome of claims 1-15 wherein said neutral phospholipid is distearoylphosphatidylcholine (DSPC) or dimyristoylphosphatidylcholine (DMPC).

17. ) The liposome of claims 1-16 wherein said negatively charged phospholipid is a phosphatidylglycerol compound, a phosphatidylserine compound, or a phosphatidylinositol compound.

18. ) The liposome of claims 1-17 wherein said negatively charged phospholipid is distearoylphosphatidylglycerol (DSPG) or dimyristoylphosphatidylglycerol (DMPG).

19. ) The liposome of claims 1-18 wherein the mean liposome diameter is in the range 50 and 400 nm.

20. ) The liposome of claims 1-19 wherein the mean liposome diameter is in the range 80 and 140 nm.

21. ) A liposome having an internalised material which comprises:

i) the liposome of claims 1-20,

ii) the irreversibly chemically modified material of claims 1 to 10.

22. ) The liposome of claim 21 wherein the internalised material is a SPECT imaging agent, an MRI contrast agent or an x-ray contrast agent.

23. ) The liposome of claim 21 wherein the internalised material is a drug.

24. ) A kit for the preparation of the liposome of claims 21-22 which comprises:

i) a first compartment containing the liposome of claims 1-9 and claims 11-20, and

ii) a second compartment containing the internalisable material of claims 6 to 9 or a precursor thereof.

25. ) A kit for the preparation of the liposome of claim 23 which comprises:

i) a first compartment containing the liposome of claims 1-5 and claims 10-20, and

ii) a second compartment containing the internalisable material of claim 10 or a precursor thereof.

26. ) The kit of claims 24 or 25 wherein the liposome of said first compartment and the material or precursor thereof of said second compartment are lyophllised.

27. ) The kit of claims 24 to 26 wherein said first compartment further comprises a cryoprotectant.

28. ) The kit of claim 27 wherein the cryoprotectant is sucrose.

29. ) Use of the liposomes prepared by the kit of claim 22 for imaging infection, inflammation or tumour in a human.

30. ) The use of claim 29 wherein the infection and/or inflammation in a human includes osteomyleitis, inflammatory bowel disease and appendicitis.